卡培他滨节拍化疗在标准化辅助治疗后的早期三阴性乳腺癌患者的临床疗效及安全性研究  

Clinical efficacy and safety of capecitabine metronomic chemotherapy in early triple-negative breast cancer patients after standard adjuvant therapy

作　　者：姜熊 李龙[1] 刘青旭 晁腾飞 Jiang Xiong;Li Long;Liu Qingxu;Chao Tengfei(Department of Oncology,Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology,Wuhan 430030,Hubei,China)

机构地区：[1]华中科技大学同济医学院附属同济医院肿瘤科,湖北武汉430030

出　　处：《中国医学前沿杂志（电子版）》2023年第5期53-57,共5页Chinese Journal of the Frontiers of Medical Science(Electronic Version)

基　　金：国家自然科学基金面上项目(81772830)。

摘　　要：目的探讨卡培他滨在标准化辅助治疗后的早期三阴性乳腺癌患者中的临床疗效及安全性。方法回顾性收集2015年9月至2022年6月期间于华中科技大学同济医学院附属同济医院就诊的早期三阴性乳腺癌患者资料,根据标准化辅助治疗后是否服用卡培他滨(节拍治疗1年),分为卡培他滨组(78例)及对照组(82例),主要研究终点为无进展生存期(progression-free survival,PFS),随访记录服药期间的安全性数据,包括不良反应及生活质量评分。结果共入组160例患者,中位随访46个月,观察到28例复发事件,其中卡培他滨组4例,对照组24例。卡培他滨组PFS生存获益明显高于对照组(HR=0.32,95%CI:0.15~0.70,P=0.029)。卡培他滨相关的常见不良事件是骨髓抑制、手足综合征、肝功能异常。生活质量评分量表结果显示,两组无明显差异(P>0.05)。结论在接受标准化辅助治疗的早期三阴性乳腺癌患者中,卡培他滨节拍化疗,与对照组相比,具有较显著的生存获益;不良反应较轻,生活质量未见明显下降。Objective To investigate the clinical efficacy and safety of capecitabine metronomic chemotherapy in early triple-negative breast cancer patients after standard adjuvant therapy.Methods Clinical data of early-stage triple-negative breast cancer patients in Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology from September 2015 to June 2022 were collected.According to the combination of capecitabine after standard adjuvant therapy,patients were divided into capecitabine group(78 cases)or control group(82 cases),the primary endpoint was progression-free survival(PFS).Furthermore,the safety data during medication,including adverse reactions and quality of life scores were recorded.Results A total of 160 patients were enrolled and followed up for a median of 46 months.Twenty-eight recurrence events were observed,of which 4 events occurred in the capecitabine group and 24 events in the control group.The capecitabine group had a significantly higher PFS benefit than the control group(HR=0.32,95%CI:0.15~0.70,P=0.029).The common adverse events related to capecitabine were bone marrow suppression,hand-foot syndrome,and liver dysfunction.The quality of life scores showed no significant difference between the two groups(P>0.05).Conclusion In early stage triple-negative breast cancer patients who received standard adjuvant therapy,low-dose capecitabine metronomic therapy for one year may be benificial compared with the control group.Capecitabine treatment is well tolerable and maintain the quality of life compared with control group.

关 键 词：卡培他滨 三阴性乳腺癌 节拍化疗 

分 类 号：R737.9[医药卫生—肿瘤]